Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Avalo Therapeutics (AVTX) EBIT Margin (2016 - 2025)

Avalo Therapeutics' EBIT Margin history spans 12 years, with the latest figure at 33461.02% for Q4 2025.

  • For Q4 2025, EBIT Margin fell 2652820.0% year-over-year to 33461.02%; the TTM value through Dec 2025 reached 123601.69%, down 10806564.0%, while the annual FY2025 figure was 123601.69%, 10806609.0% down from the prior year.
  • EBIT Margin reached 33461.02% in Q4 2025 per AVTX's latest filing, down from 6932.81% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 27.39% in Q3 2022 to a low of 33461.02% in Q4 2025.
  • Average EBIT Margin over 5 years is 4782.2%, with a median of 1588.98% recorded in 2023.
  • Peak YoY movement for EBIT Margin: surged 721400bps in 2022, then crashed -2652820bps in 2025.
  • A 5-year view of EBIT Margin shows it stood at 8202.28% in 2021, then surged by 88bps to 988.28% in 2022, then plummeted by -36bps to 1341.16% in 2023, then crashed by -417bps to 6932.81% in 2024, then plummeted by -383bps to 33461.02% in 2025.
  • Per Business Quant, the three most recent readings for AVTX's EBIT Margin are 33461.02% (Q4 2025), 6932.81% (Q4 2024), and 5165.06% (Q3 2024).